Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 16/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870003 | 0.90 | ALDH1A1 (0.41) | PTGESKCNH2ATMATRPRKCQ | |
| SCHEMBL2744399 | 0.84 | KCNH2 (0.44) | KCNH2ATMATRPRKCQMEN1 | |
| SCHEMBL3869962 | 0.82 | KCNH2 (0.42) | LRRK2KCNH2ATMATR | |
| SCHEMBL1486803 | 0.81 | PARP14 (0.46) | KCNH2ATMATRPRKCQMEN1 | |
| SCHEMBL30074835 | 0.79 | PTGES (0.44) | PTGESALDH1A1LMNA | |
| SCHEMBL20475933 | 0.79 | PTGES (0.44) | PTGESALDH1A1LMNA | |
| SCHEMBL3867867 | 0.78 | PTGES (0.36) | PTGESMEN1ALDH1A1LMNAHTT | |
| SCHEMBL3861427 | 0.78 | PTGES (0.36) | PTGESMEN1ALDH1A1LMNAHTT | |
| SCHEMBL3861428 | 0.78 | PTGES (0.36) | PTGESMEN1ALDH1A1LMNAHTT | |
| SCHEMBL2113617 | 0.77 | KCNH2 (0.41) | LRRK2KCNH2ATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1968587-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | Coley Pharmaceutical, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1851218-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1850849-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | Coley Pharmaceutical Group, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091567-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | PTGES 44/4885LRRK2 4713/4885KCNH2 4722/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | PTGES 361/4885LRRK2 4280/4885KCNH2 3353/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | PTGES 296/4885LRRK2 3515/4885KCNH2 4354/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | PTGES 296/4885LRRK2 3515/4885KCNH2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.